When Hospital Growth Meets Antitrust Law: Mergers, Physician Acquisitions, Market Power, and Board Deal Governance, a Narrative Review

A board packet may describe an acquisition target as essential to regional scale, a platform for better payer negotiations, or the final independent referral source needed to complete a network. Those statements may be ordinary strategy language, but they also can become evidence about rivalry, network necessity, control of referrals, and the expected source of transaction value. Antitrust readiness therefore begins before a letter of intent, not when counsel opens an HSR form.

The governing thesis is direct. A hospital transaction is not made defensible by a benevolent mission, nonprofit status, rural need, favorable patient-origin map, or federal filing. It is defensible only when the board can show, from evidence created before challenge, that it understood how the parties compete, tested plausible product and geographic markets, assessed local and nonlocal harm theories, preserved independent conduct before closing, substantiated merger-specific benefits, respected federal and state review paths, and retained a credible alternative if regulators or courts reject the deal.

Five propositions follow. First, market definition is an analytical claim, not a service-area map. Hospital competition occurs through payer-network bargaining and through patient and clinician choice. Second, reportability and legality are separate. HSR is a notification and waiting regime, while Section 7 can reach a nonreportable or consummated acquisition. Third, structure does not defeat substance. Asset purchases, member substitutions, physician employment, professional-services agreements, management-service organizations, joint ventures, contracting affiliations, and minority rights can alter control or incentives. Fourth, claimed access, quality, workforce, cost, and capital benefits require verifiable proof and a less restrictive alternatives analysis. Fifth, the board record is part of legal readiness because it should reveal what was tested, who was accountable, and why the organization could proceed, modify, defer, or stop.

This article addresses the period before signing and closing. It does not cover EHR migration, culture integration, workforce harmonization, or general post-closing execution. It also does not determine whether a particular transaction is lawful. That judgment requires current counsel, market-specific economics, complete facts, and publication-day verification of volatile federal and state rules.

This single-author focused narrative review used legal and empirical searches completed through August 14, 2026. Legal sources were prioritized in the following order: enacted federal and state law, controlling appellate decisions, current official FTC and DOJ materials, agency case records and court-approved orders, representative state program pages, and secondary explanations. Peer-reviewed studies and government evidence syntheses were used for price, cost, quality, labor, physician-integration, cross-market, and remedy questions. Backward citation review from leading hospital-merger decisions and major empirical papers supplemented targeted searches.

The review preserves an authority hierarchy. A statute or binding holding is law within its scope. The joint 2023 Merger Guidelines describe current agency enforcement analysis but do not bind courts [5,6]. A complaint states allegations. A proposed consent or agreement in principle is not a final adjudication. A final order or judgment resolves the matter on its stated terms, often without a trial finding on every allegation. FTC or DOJ staff comments are advocacy or policy analysis. Empirical studies estimate effects in defined samples and do not determine the legality of a particular acquisition.

The review covers U.S. hospital, physician-practice, outpatient, and closely related health-care transactions. It focuses on market definition, local and cross-market theories, serial and vertical acquisition, labor monopsony, HSR, state transaction review, state-action immunity, COPAs, benefits, distress, remedies, gun-jumping, and board governance. Tax, Stark Law, Anti-Kickback Statute, reimbursement, licensure, charitable-asset, and certificate-of-need questions appear only where they alter competitive facts or create parallel transaction gates. State examples are illustrative, not a 50-state survey. No meta-analysis, registered protocol, formal risk-of-bias instrument, or transaction-specific market study was performed.

Clayton Act Section 7 prohibits an acquisition when, in any line of commerce and section of the country, its effect may be substantially to lessen competition or tend to create a monopoly [1]. The statute is preventive. It addresses probable incipient harm, not only a monopoly already completed. A board’s public-service motivation can matter to the factual narrative, but good intent does not substitute for analysis of market structure, bargaining leverage, entry, quality, capacity, labor, or likely competitive effects.

Other statutes remain relevant. Sherman Act Section 1 reaches agreements that unreasonably restrain trade, including unlawful pre-closing coordination and potentially restrictive payer-contract terms. Section 2 addresses monopolization, attempted monopolization, and conspiracy to monopolize [3]. FTC Act Section 5 authorizes the FTC to pursue unfair methods of competition within its statutory jurisdiction [4]. Genuine charitable nonprofits can present a more limited FTC Act conduct-jurisdiction question, but that nuance does not create a Clayton Act merger exemption. DOJ and state attorneys general also possess enforcement authority.

Nonprofit status, public ownership, certificate-of-need regulation, and charitable purpose therefore are not merger safe harbors. The Eleventh Circuit in University Health rejected a presumption that nonprofit hospitals would not exercise market power after merger [28]. Current practice points the same way. In June 2026, the FTC announced a proposed consent in the Ascension/AmSurg matter that would require seven ambulatory-surgery-center divestitures and 10 years of prior notice. That proposal is not final, but it demonstrates that nonprofit identity does not end the competitive inquiry [22].

The FTC and DOJ continue to use the 2023 Merger Guidelines as their announced framework [5,6]. The Guidelines organize multiple theories, including structural concentration, lost head-to-head competition, coordination, loss of a potential entrant, foreclosure of rivals, entrenchment, a trend toward consolidation, a series of acquisitions, buyer power, and partial ownership. Guideline 1 identifies two agency structural presumptions after the relevant market has been defined: post-merger HHI above 1,800 with an increase above 100, or merged-firm share above 30 percent with an HHI increase above 100 [5]. These are rebuttable agency presumptions, not statutory zones of automatic illegality.

Market shares and HHI also are not the only evidence. Payer testimony, diversion, network necessity, ordinary-course documents, internal win-loss records, capacity, rate negotiations, referral patterns, quality investment, entry barriers, and direct evidence of rivalry can matter when a share measure is disputed. A board that receives only one concentration table has not received an antitrust analysis. It has received one output that depends on the market definition placed underneath it.

Current enforcement is active but not accurately described as a refusal to settle every matter. DOJ stated in 2025 that it had restored early termination for uncontroversial HSR reviews and was willing to use targeted consent decrees where appropriate [57]. At the same time, federal agencies have continued to litigate or resolve matters involving anesthesia roll-ups, home health and hospice, ambulatory surgery, disability-care facilities, hospital payer-contract restrictions, travel-nurse staffing, and medical devices [19,21,22,23,24,25,26,27]. The practical conclusion is not that every deal will be blocked. It is that legal process, remedy design, and the quality of pre-closing evidence remain material.

Section 7 analysis requires a line of commerce and a section of the country. For hospital transactions, that means both product and geographic market analysis. Plausible products can include a cluster of inpatient general acute-care services sold to commercial health plans; a distinct service line such as inpatient obstetrics; a physician specialty; outpatient surgery, imaging, oncology, behavioral health, home health, hospice, or post-acute care; the purchase of specialized labor; or access to a facility, referral channel, or other input used by rivals.

Hospital competition often has two linked stages. Health plans assemble provider networks and negotiate reimbursement. Patients and referring clinicians then choose among the providers available in those networks. The hypothetical-monopolist framework asks whether control of a candidate set would permit a small but significant nontransitory worsening of price or another competitive term. In a hospital case, the question can concern negotiated rates, quality, capacity, choice, service, innovation, or wages, not only the cash price paid by an individual patient.

Patient origin and travel data can inform the analysis, but they do not define the market by themselves. Patients may travel outward for tertiary services even though local hospitals remain indispensable to payer networks for routine care. Patients may also be unwilling or unable to travel in response to a negotiated rate increase they never observe directly. A broad area that captures a high percentage of historical admissions can therefore overstate the alternatives available to a health plan after the merger.

The modern hospital cases make that caution concrete. In Penn State Hershey, the Third Circuit rejected an overly broad geographic analysis and emphasized the commercial realities of payer-network bargaining [12]. In Advocate/NorthShore, the Seventh Circuit likewise focused on substitution and the hospitals needed for a marketable network [13]. The FTC’s successful preliminary-injunction litigation in Hackensack Meridian/Englewood further illustrates the importance of close competitive alternatives and payer evidence [14]. These decisions do not establish one universal mileage radius. They establish that a clinical service area, community-needs region, management territory, and antitrust market are different concepts.

A defensible board inquiry should test at least six possible boundaries around one transaction:

1. Patient-service product. Are general acute-care services appropriately clustered, or does a distinct specialty require separate treatment?
2. Patient geography. Where can patients realistically turn, accounting for urgency, referral, insurance, transportation, and clinical complexity?
3. Payer network. Could a health plan sell a commercially viable network without either party, and what is the loss if the parties negotiate together?
4. Physician specialty. How many independent practitioners, practice sites, and realistic entrants remain for each affected specialty?
5. Referral and input access. Can control of employed physicians, ambulatory sites, beds, data, or facilities impair a rival’s path to patients?
6. Labor. Where can nurses, pharmacists, physicians, technicians, and other workers realistically seek alternative employment, and on what terms?

The relevant evidence differs for each boundary. Payer contracting files may be central to a network claim. Scheduling, commuting, vacancy, credentialing, and specialty-specific recruiting may be central to a labor claim. Physician panels and referral leakage may matter to a vertical theory. Entry must be timely, likely, and sufficient in the actual market. A theoretical license, vacant parcel, or distant health system is not necessarily an effective competitive substitute.

Board minutes should therefore avoid using the phrase “our market” without definition. Management may mean a service area used for planning, while counsel and economists need a product and geography tied to the mechanism of competitive harm. The board should receive alternatives, sensitivity testing, and the strongest plausible contrary case, not only the boundary that makes the transaction look least concentrated.

5.1 Local horizontal hospital overlap

The classic hospital theory is that two close substitutes become one negotiating entity, leaving health plans and patients with fewer credible alternatives. The possible harm includes higher negotiated rates, reduced service or capacity rivalry, lower quality, weaker innovation, or easier coordination. ProMedica resulted in an FTC divestiture order upheld by the Sixth Circuit after the acquisition of St. Luke’s Hospital [15]. The proposed Novant/Community Health Systems transaction was abandoned in 2024 after the Fourth Circuit enjoined closing pending appeal. The FTC’s alleged shares and harms in that matter were never final merits findings [18]. Together, these matters show both the durability of the local-overlap theory and the need to label procedural posture accurately.

5.2 Physician-practice acquisitions and referral control

A physician deal can affect competition even when the hospital does not acquire another hospital. Risks can arise from high specialty shares, loss of independent contracting, control of referrals, facility-based billing, foreclosure of rival hospitals, or additional leverage with payers. Saint Alphonsus v. St. Luke’s involved a consummated acquisition of Saltzer Medical Group. The court accepted that the combination could produce patient benefits, yet held the acquisition unlawful and ordered divestiture because the claimed efficiencies did not overcome the competitive harm on the record [16]. The FTC and North Dakota challenge to Sanford’s proposed acquisition of Mid Dakota Clinic shows a similar Section 7 screen for physician specialties [17]. Clinical integration can be genuine, but the label does not resolve whether the same benefit is achievable through a less restrictive structure.

5.3 Cross-market system power

Hospitals that do not compete for the same individual patients can still have common commercial payers and employers. A combination may increase bargaining leverage if a plan needs a broad system across several regions, if employers value systemwide coverage, or if multimarket contact changes negotiating incentives. This is not the same as a local horizontal overlap. Peer-reviewed evidence increasingly supports a board screen, but adjudicated hospital-merger doctrine is less developed.

Dafny, Ho, and Lee found within-state cross-market combinations from 1996 through 2012 associated with roughly 7% to 9% higher prices, while out-of-state combinations did not show a statistically significant increase in their dataset [45]. Arnold and colleagues studied 214 treated and 955 comparison hospitals and reported cross-market acquirer prices 12.9% higher at six years, with a 95% confidence interval from 0.6% to 26.6%. The estimate for serial acquirers was 16.3%, with a 95% confidence interval from 4.8% to 29.1% [46]. Lewis and Pflum studied out-of-market acquisitions from 2000 through 2010 and reported acquired-hospital prices about 17% higher relative to unacquired stand-alone hospitals and nearby-rival prices about 8% higher [47]. These are different populations, designs, outcomes, and horizons. They justify fact development, not a conclusion that every nonoverlapping acquisition is unlawful.

5.4 Serial acquisitions and roll-ups

A series of individually small transactions can implement a cumulative consolidation strategy. Guideline 8 directs the agencies to examine the series or pattern, including its history and strategic objective [5]. This matters for physician practices, anesthesia groups, ambulatory sites, post-acute businesses, and local service platforms whose individual purchases may fall below HSR thresholds.

The USAP matter is the prominent health-care example. The FTC alleged a multi-year roll-up and related agreements in Texas anesthesia markets. The Commission approved a final order with Welsh Carson in May 2025 [20]. As to USAP, the FTC announced an agreement in principle in April 2026, but the terms remained to be executed and the litigation remained listed as pending at the research cutoff [19]. Neither the complaint allegations nor an agreement in principle should be restated as a final adjudication against every party. The governance lesson is narrower and stronger: the board must map prior acquisitions, related entities, reserved rights, contracting affiliations, and the cumulative market trajectory.

5.5 Vertical and adjacent-market control

Hospital acquisition of physicians, surgery centers, home-health agencies, post-acute providers, or other inputs can produce coordination benefits, but it can also create foreclosure, steering, information, and raising-rivals’-cost concerns. The questions are mechanism-specific. Can the combined firm deny or degrade a rival’s access to referrals, clinicians, facilities, network participation, data, or another necessary input? Will it obtain competitively sensitive information from organizations that remain competitors? Does the structure enable tying or all-or-nothing contracting? Can a narrower contract, clinically integrated network, shared-service arrangement, or joint venture achieve the same coordination benefit?

Current adjacent-market enforcement illustrates the range. The UnitedHealth/Amedisys final judgment required divestiture of at least 164 home-health and hospice facilities and imposed a civil penalty tied to an inaccurate HSR certification [21]. The FTC finalized the Sevita/BrightSpring consent order in June 2026, requiring divestiture of 128 intermediate-care facilities and related assets [23]. These are not acute-care hospital precedents, and the final orders resolve allegations on their stated terms rather than adjudicate every allegation after trial. They do show that narrow service markets and operationally complete remedies can be central in health care.

Payer-contract conduct can also matter independently of a merger. DOJ sued OhioHealth in February 2026 over alleged all-or-nothing and related restrictions, then filed a proposed settlement in June that would prohibit specified terms and use a monitor for five years [26]. DOJ’s March 2026 complaint against New York-Presbyterian similarly alleged contract restrictions affecting exclusion, tiering, and patient incentives; that matter remained pending [27]. The alleged conduct is not a finding. For deal governance, however, contract language and network strategy belong in the competition fact base.

5.6 Labor monopsony, innovation, and partial interests

A merger can reduce competition for nurses, pharmacists, physicians, technicians, or other workers even if the patient-services theory is disputed. Guideline 10 expressly addresses buyer competition, including employers competing for labor [5]. Relevant labor markets can be narrower than patient markets because occupation, license, shift, specialty, commuting, credentialing, and family constraints affect substitution. Competitive terms include wages, benefits, scheduling, staffing, professional development, mobility, and working conditions.

The FTC’s concern about the Aya/Cross Country transaction involved travel-nurse hiring and managed services. The parties terminated the deal in December 2025 after staff raised concerns, with no merits finding [25]. In medical devices, a district court preliminarily enjoined Edwards/JenaValve in January 2026 on an innovation-competition theory, and the buyer abandoned the transaction [24]. These examples are outside a traditional hospital-overlap case, but they reinforce the need to examine upstream competition and future innovation.

The nationwide FTC Noncompete Rule is not in effect and not enforceable. The FTC dismissed its appeals in September 2025 [58]. That posture does not prevent case-specific federal or state scrutiny. The FTC separately sent warning letters to health-care employers and staffing companies concerning potentially unlawful noncompetes [59]. The 2025 FTC/DOJ Antitrust Guidelines for Business Activities Affecting Workers are agency guidance, not a statute or judicial holding [60].

Minority interests, board observation rights, reserved powers, professional-services agreements, MSO structures, contracting affiliations, joint ventures, and clinically integrated networks also can change control, incentives, or access to sensitive information. A noncontrolling label is not enough. The board should ask which decisions require consent, which economics are shared, who sees payer and strategy data, what conduct is coordinated, and whether either party remains an independent competitive option.

The Hart-Scott-Rodino Act requires notification and a waiting period for covered transactions [2]. It is procedural. Filing does not establish legality, expiration of the waiting period is not an approval, and a transaction that is nonreportable or exempt can still be investigated under Section 7. Valuation, aggregation, control, exemptions, and the identities of the acquiring and acquired persons require application of the rules to the actual structure.

As of August 14, 2026, the minimum size-of-transaction threshold is $133.9 million, effective February 17, 2026. The size-of-person figures are $26.8 million and $267.8 million, and the level above which the size-of-person test generally does not apply is $535.5 million. Fees range from $35,000 to $2.46 million across the current transaction bands [7]. These figures adjust annually. They should be rechecked against the FTC’s live threshold page at signing, filing, and publication.

The filing form is unusually volatile. A federal district court vacated the expanded form on February 12, 2026, and an appellate court denied a stay on March 19. The agencies currently accept the form and instructions used before February 10, 2025 and allow voluntary use of the expanded 2025 materials [8]. The FTC and DOJ opened a new inquiry and may pursue rulemaking [9]. This is a current procedural posture, not an evergreen instruction.

The ordinary initial review period is commonly 30 days, although structure-specific rules can differ. A Second Request extends the pre-closing process until substantial compliance and the applicable waiting period. DOJ’s July 2026 targeted process and model timing agreement are process tools, not promises of clearance and not FTC-wide rules [10]. A board calendar should budget for investigation, preservation, production, privilege review, executive time, public communication, and delayed closing.

Accuracy and independence are separate controls. A 2026 FTC matter proposed $12 million in penalties for alleged failure to file involving interrelated payments around a threshold. The resolution was proposed, not final at the cutoff [56]. The lesson is to analyze the whole transaction and certify accurately. Before closing, parties must remain competitors. Clean teams, data minimization, counsel-approved protocols, and narrow planning access can support legitimate preparation. The buyer cannot take operational control, coordinate prices, allocate patients or payers, or direct ordinary-course competitive decisions. A 2025 gun-jumping settlement, outside health care, underscores that premature transfer of control can produce substantial penalties [11].

The board should see three separate answers: whether HSR filing is required, whether the transaction may substantially lessen competition, and which state or sector-specific reviews apply. A “no filing” result answers only the first.

State authority can arise from antitrust law, nonprofit and charitable-asset law, facility licensure, certificate-of-need statutes, insurance law, professional-entity rules, material-change notice, cost-and-market-impact review, and COPA legislation. These are parallel gates, not one generic attorney-general approval. Coverage can turn on provider, patient, asset, revenue, licensure, control, or ownership facts, and can reach transactions far below HSR thresholds.

Current examples show the variation. Illinois generally requires covered facilities and provider organizations to provide at least 30 days’ notice; an HSR-reportable transaction can require a concurrent copy to the attorney general [34]. California’s Office of Health Care Affordability generally uses a 90-day material-change notice, and AB 1415 expanded covered entities and control structures in 2026 [35]. New York Article 45-A generally uses 30-day notice, a rolling 12-month series concept, and a $25 million in-state gross-revenue threshold, subject to statutory definitions and exclusions [36]. Minnesota’s current program uses revenue-based coverage with at least 60 days’ notice for specified larger transactions and potential extension [37].

Washington’s June 2026 expansion broadened transaction and ownership coverage, added fees and completion reporting, and retained specified state-patient revenue connections [38]. Rhode Island’s January 2026 medical-practice rule reaches defined private-equity ownership or control, groups of eight or more listed clinicians, and creation of certain MSO or contracting structures [39]. Oregon operates a health-care market-oversight program with notice and potential review [40]. Indiana has a provider-transaction notice law and a separate COPA pathway [41,42]. The examples are not a nationwide inventory, and notice must not be mislabeled as substantive approval.

State action and COPAs

State-action immunity is narrow. For private actors, the challenged restraint generally must implement a clearly articulated state policy to displace competition and be actively supervised by the state. FTC v. Phoebe Putney rejected the argument that general Georgia hospital-authority powers clearly articulated permission for an anticompetitive hospital acquisition [29]. North Carolina State Board of Dental Examiners v. FTC reinforces that a board controlled by active market participants needs active supervision to claim immunity [30]. A state license, certificate of need, public label, or ordinary approval does not establish the doctrine by itself.

A COPA can create a state-supervised displacement of competition, but the board needs precise answers about the statute, supervisor, power to disapprove, monitored prices, quality, access, service, investment, workforce, reporting, remedies, and the consequences of expiration. FTC staff generally argues that COPAs substitute regulation for competition, but that policy position is not binding law [31]. Garmon and Bhatt’s study of four older hospital COPAs found mixed results: some price restraint while oversight was active, opportunities for evasion under weak design, and large price increases after expiration or repeal in some settings, with a quality decline in the transaction for which quality data were available [32]. In 2026, FTC staff separately warned that ending Ballad Health supervision without restored competition or alternative oversight could remove active supervision while leaving monopoly structure intact [33]. That is a transition warning, not an endorsement of creating COPAs.

The empirical record is strongest as a direction for inquiry, not as a transaction verdict. Using commercial-claims data, Cooper and colleagues found monopoly hospitals priced about 12% above hospitals in markets with four or more rivals. In a 366-transaction subsample from 2007 through 2011, prices rose by more than 6% after mergers of hospitals within five miles [43]. Brand, Garmon, and Rosenbaum studied 558 mergers from 2009 through 2016 and estimated an average commercial-price effect of roughly 5%, with substantial heterogeneity. They did not find higher-than-average increases among mergers that were not HSR reportable, but that does not make small deals harmless [44].

Cross-market estimates must remain study-specific. Dafny, Ho, and Lee reported roughly 7% to 9% higher prices for within-state cross-market combinations from 1996 through 2012 [45]. Arnold and colleagues reported 12.9% higher acquirer prices at six years, with wide confidence intervals, and 16.3% for serial acquirers [46]. Lewis and Pflum’s analysis of 2000 through 2010 out-of-market acquisitions reported about 17% higher acquired-hospital prices relative to unacquired stand-alone hospitals and about 8% higher nearby-rival prices [47]. These results should never be averaged into one synthetic “merger effect.”

Physician acquisition shows a related but distinct pattern. Capps, Dranove, and Ody analyzed 2007 through 2013 claims and found acquired-physician service prices increased 14.1% on average, with nearly half attributable to payment rules; primary-care integration was associated with 4.9% higher enrollee spending [48]. A physician-service price is not a hospital-admission price, and a payment-policy component is part of the estimate.

Quality evidence is multidimensional. Beaulieu and colleagues compared 246 acquired hospitals with 1,986 controls. Patient experience declined by 0.17 standard deviations, while mortality and readmission did not show significant differential improvement and process evidence was inconclusive [49]. That supports “no broad average quality improvement detected,” not “quality always declines.” A single-hospital quality-improvement study by Wang and colleagues followed 181,252 patients and associated a full-integration merger with lower mortality, but it lacked a control hospital and could not isolate the contribution of individual interventions [50]. The result is a useful counterexample to categorical claims, not a population average.

Cost savings also require separation from price and benefit. Schmitt estimated 4% to 7% average cost reductions at acquired hospitals, with no comparable systemwide savings at acquirers and limited evidence of savings for in-market mergers [51]. Lower cost can support a benefit claim, but it does not show that negotiated prices fell, that quality improved, or that the savings were merger-specific.

Labor effects are plausible and heterogeneous. Prager and Schmitt found that mergers in the top quartile of employer-concentration increases were followed by annual wage growth 1.7 percentage points slower for nursing and pharmacy workers with industry-specific skills, corresponding to about 6.8% lower wages after four years. They did not detect the same wage effect in the other merger groups examined [52]. Using 1990s California data, Currie, Farsi, and MacLeod found little evidence of broad wage reductions after hospital-chain takeovers but did find increased patients per nurse, suggesting that employer power may appear through workload as well as nominal wages [53].

Every study has boundaries. Merger selection is not random; commercial claims exclude many payers; quality measures observe selected outcomes; and results vary with market, payer, distance, specialty, transaction type, and follow-up. Historical average effects cannot decide a 2026 transaction. The defensible synthesis is that consolidation is frequently associated with higher commercial prices, broad consistent quality gains have not emerged in average-effect studies, particular integrations can improve selected outcomes, and labor and cost effects vary materially.

A claimed benefit should be merger-specific, verifiable, timely, durable, and sufficient to prevent the threatened competitive harm. It should not arise from worsening wages, access, price, or another competitive term. For each access, quality, capital, workforce, or cost claim, the board should receive a baseline, owner, investment, milestone, metric, verification method, less restrictive alternatives analysis, and explanation of how patients, workers, payers, or competition receive the benefit. “Integrated care” is an objective, not evidence.

Financial distress needs similar discipline. The failing-firm defense is narrow: grave probability of failure, dim or nonexistent prospects for successful reorganization, and no reasonable less anticompetitive purchaser after good-faith search [5]. That differs from a weakening-competitor argument, a rural-access policy case, and preference for the highest or fastest bid. Closure risk and service fragility can be important, but contemporaneous cash forecasts, board alternatives, buyer outreach, financing options, and service obligations must support the claim.

Remedy feasibility belongs before authorization. Structural relief requires a viable business, capable independent buyer, people, licenses, payer contracts, referral streams, data, IT, working capital, and transitional services. The FTC’s 2017 retrospective covered 89 merger orders from 2006 through 2012. In its 50-order case-study component, the agency reported that more than 80% maintained or restored competition, while complete ongoing-business divestitures were more reliable than limited-asset packages. It was an agency retrospective across industries, not a hospital-specific randomized study [54].

Hospital and adjacent cases show varied outcomes. St. Luke’s/Saltzer and ProMedica produced divestiture [15,16]. UnitedHealth/Amedisys produced a broad final structural remedy [21]. Evanston Northwestern used separate negotiating teams after a long-consummated merger made divestiture unusually difficult; it does not promise a pre-closing conduct solution [55]. In Phoebe Putney, certificate-of-need barriers prevented structural restoration after consummation [29]. Rate caps, firewalls, anti-tying rules, access promises, and monitors can address selected facts but require long-term administration and may leave structure intact. If a viable remedy cannot preserve competition, the realistic decision may be litigation, substantial modification, or abandonment.

The following model is an executive operating design, not a new legal test or safe harbor. Each gate should have a named owner, documented evidence, an escalation rule, and a stop criterion.

Gate 1: strategic purpose and alternatives

Management should define the problem being solved and compare acquisition, affiliation, joint venture, service contract, organic expansion, capital support, partnership, and no-deal alternatives. Strategy owns the business case; general counsel tests how it is expressed. Stop when transaction value depends principally on eliminating an independent rival, controlling referrals, or forcing payers rather than on a defensible operating benefit.

Gate 2: transaction perimeter

Map every entity, asset, license, physician group, payer contract, MSO, ambulatory site, referral relationship, joint venture, minority interest, reserved power, and governance right. Corporate development owns the map, with counsel and compliance validation. Test control and incentives rather than labels. Stop when the team cannot explain who controls competitive decisions or which related transactions must be aggregated.

Gate 3: competition fact base

Under counsel’s direction, an economist and operating leaders should analyze product and geographic candidates, payer-network substitution, patient and referral diversion, rates, margins, quality, capacity, physician specialties, outpatient overlap, cross-market common-payer exposure, labor alternatives, entry barriers, prior acquisitions, and ordinary-course rivalry. The board should receive sensitivity analyses and the strongest plausible agency case. Stop when a critical market or harm theory remains untested.

Gate 4: documentary integrity

Train directors and deal personnel before documents are created. Records must be accurate, specific, preserved, and consistent with the actual analysis. Do not sanitize unfavorable facts, create advocacy unsupported by operations, or obstruct discovery. Counsel owns preservation and privilege controls; every executive owns accuracy. Stop for material misstatement, missing ordinary-course evidence, uncontrolled messaging, or preservation failure.

Gate 5: benefits dossier

Clinical, finance, workforce, and operating leaders should document each claimed benefit through baseline, investment, owner, timing, measure, verification, merger specificity, and less restrictive alternatives. Separate commitments from aspirations and identify who receives the benefit. Stop when the benefit cannot be measured, depends on anticompetitive leverage, or is reasonably achievable through a narrower arrangement.

Gate 6: filing and review map

General counsel should maintain one current calendar for HSR, state notice, attorney-general review, nonprofit or charitable-asset process, facility and CON review, professional-entity restrictions, COPA, payer consent, hearings, outside dates, and public disclosure. Recheck live rules before signing and filing. Stop when the transaction agreement, financing, or public communication assumes a closing date that the legal review path cannot support.

Gate 7: pre-closing independence

Compliance and counsel should implement a written gun-jumping protocol covering clean teams, minimum necessary data, redaction, permitted planning, prohibited coordination, ordinary-course covenants, training, and escalation. Audit adherence through closing. Stop data flow or planning activity when it permits either party to influence prices, contracting, staffing, service, customers, or other competitive conduct before lawful control transfers.

Gate 8: remedy and exit feasibility

Identify possible divestiture packages and credible buyers before the board authorizes the definitive agreement. Test whether people, licenses, payer relationships, referral flow, records, data, IT, branding, transition services, capital, and working assets can support an independent competitor. Finance should quantify delay, litigation, remedy, and abandonment. Stop when the only proposed package is operationally dependent on the merged firm or when the agreement leaves no credible exit from unacceptable relief.

Gate 9: final board decision record

The final paper should state what competition changes, which markets and 2023 Guideline theories are plausible, what state regimes apply, whether claimed benefits are verifiable and merger-specific, whether distress meets the actual standard, whether a remedy preserves a viable competitor, what the fallback is, and who owns independence and filing accuracy. The board should record a reasoned decision to approve, modify, defer, or stop, with dissent and conflicts handled under governance policy.

The assurance statement can be concise: the board reviewed the transaction’s purpose, alternatives, competitive effects, legal pathways, evidence-supported benefits, independence controls, remedy feasibility, and exit options, and did not rely on mission, tax status, HSR filing, or state process as a substitute for substantive analysis. A board should not approve a transaction whose value depends on a competitive effect it cannot defend in daylight.

This is a focused narrative review, not a systematic review, meta-analysis, 50-state survey, or transaction-specific opinion. The legal environment is volatile, especially the HSR form and state material-change regimes. Agency guidance can change and does not bind courts. Pending complaints and proposed settlements may develop after the cutoff. Empirical studies use different designs, samples, outcomes, and periods, and historical average effects cannot establish causation or legality for one transaction. Cross-market theories have a growing empirical base but less adjudicated hospital-merger precedent than local horizontal theories. Current counsel must reverify federal thresholds, filing instructions, case status, and every relevant state requirement before publication and before action.

Hospital growth, clinical integration, and lawful competition are related but not interchangeable. A transaction can respond to real capital, workforce, access, or quality needs and still reduce rivalry. It can also produce genuine benefits that survive rigorous testing. The board’s job is not to predict an agency slogan. It is to create a reliable pre-closing record about how the parties compete, what changes, what benefits require the transaction, which review paths apply, how independence is protected, and whether a viable remedy or exit exists.

The decisive evidence is usually created before challenge, when leaders still can choose a narrower structure, preserve alternatives, improve the proof, or walk away. That is why antitrust belongs in the board’s decision system before the deal is signed, not in a filing workstream after the strategic commitment is already irreversible.